Detecting Hospital M&A Synergies Before They’re Announced: A Rate-Based Event Strategy
Hospital mergers have been the most reliable source of healthcare sector alpha over the past decade. They have also been ...
Reading Payer Margin Through Hospital Rate Data: A Short-Side Framework for Managed Care Equities
Managed care equities trade on medical loss ratio projections, and those projections are consistently wrong at inflection points. Price transparency ...
Mapping the Reimbursement Cliff: Using MedPricer.org to Time Hospital Operator Positions
Hospital earnings are contract earnings. The quarterly EBITDA that sell-side analysts model from utilization trends and staffing costs is, at ...
What MedPricer.org Can and Cannot Tell You About Healthcare Quality
The most common misuse of hospital price data is treating it as a quality proxy. It isn't. But the relationship ...
Private Equity in Healthcare: What Negotiated Rate Data Tells Investigators That Acquisitions Don’t
Private equity's expansion into healthcare has generated substantial policy attention and inadequate empirical scrutiny. Price transparency data offers a partial ...
The Importance of Access Control in the Workplace
In healthcare settings, safety and privacy sit at the center of daily operations. The importance of access control in the ...
Conditions That Affect Medical Device Performance
Medical device testing often takes place in controlled environments where temperature, handling, setup, and user instructions are closely managed. This ...
Design That Makes Healthcare Cleanrooms Easier to Sanitize
Cleanrooms support some of the most sensitive functions in healthcare. These spaces protect medications, devices, lab work, and patient safety ...
Benefits of Utilizing Warm Water During Labor
Labor asks a lot of the body, and it can be challenging for people to find comfort as contractions intensify. ...
The Academic Medical Center Premium: What Price Data Reveals About Prestige Pricing in Hospital Markets
Academic medical centers have always charged more. The question that price transparency data now allows us to ask more precisely ...
Employer-Sponsored Insurance Is Breaking Down. Price Data Tells You Where It’s Happening First.
The entity with the most to gain from hospital price transparency is not the patient, not the insurer, and not ...
State Regulators and the Federal Data Gap: How MedPricer Fills What CMS Leaves Incomplete
Federal disclosure mandates and state regulatory authority occupy different jurisdictional spaces, and the gap between them is not an accident ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more